This activity is provided by the Society for Neuro-Oncology.

In the week following the activity, an email will be sent to attendees, with instructions and a link to claim credit/ participation certificates, from the Society for Neuro-Oncology, with the subject line: "Instructions to Claim Credit, Certificate of Participation for the 2026 SNO/ASCO CNS Metastases Conference."

Target Audience

Neuro-oncologists (both neurology and medical oncology-trained), Medical Oncologists, Neurosurgeons, Neuro-radiologists, Neuropathologists, Neuropsychologists, Radiation Oncologists, Basic and Translational Scientists, Data /AI Scientists, Computational scientists, Basic and Clinical Science Trainees, Allied Health Professionals, Palliative Care/Quality of Life Professionals, Industry Professionals, Drug Developers, Regulatory and Government Officials, Patient Advocates, Clinical research specialists, Clinical research organizations — all involved in clinical trials and patient care of patients with CNS metastases.

Statement of Need/Program Overview

The Society for Neuro-Oncology (SNO), in collaboration with the American Society of Clinical Oncology (ASCO), present this year’s SNO/ASCO CNS Metastases Conference to be held August 13-15, 2026, at the Westin Copley Place in Boston, Massachusetts. The theme is From Moonshot to Groundshot: Transforming Science into Impact and the scientific content of this dynamic event includes outstanding keynote and plenary addresses on the complex and rapidly evolving area of CNS metastases.

The program is interdisciplinary, intentionally structured to connect discovery to clinical impact across the continuum of brain and leptomeningeal metastasis care.

Sessions will address basic, translational, and clinical research defining CNS tropism and the metastatic microenvironment, highlighting advances in multidisciplinary treatment strategies, including precision neurosurgery, modern radiotherapy techniques such as stereotactic radiosurgery and FLASH, and the rational integration of systemic therapies. The agenda further examines topics which underscore the progression from scientific moonshots to ground-level changes in patient care. In addition, the latest work shown in selected scientific abstracts will be highlighted in oral presentations and the poster networking reception.

Some areas include:

• CNS-active targeted agents and immunotherapies
• device-based local therapies; tumor-treating fields
• management of acute and long-term treatment-related toxicities
• patient quality of life and survivorship
• data-driven decision-making

Educational Objectives

After participating in this CME activity, participants should be able to:

• Discuss the development of cancer therapy investigations regarding novel therapeutics for patients with CNS metastases.
• Explain the role of systemic and targeted therapy in the context of multidisciplinary care for the treatment of patients with CNS metastases.
• Discuss novel developments in local therapies for patients with CNS metastases, including advances in radiation therapy.
• Describe the role of the tumor stem cells and tumor microenvironment in CNS metastases and explore other potential mediators of CNS dissemination.
• Discuss innovative clinical trial designs incorporating recent advances such as liquid biopsy, novel prognostic biomarkers, advanced neuroimaging for the treatment of patients with brain metastases and leptomeningeal spread of cancer.
• Summarize the impacts of radiation therapy, systemic therapy, and immunotherapies on a patient survivorship and neurocognition, and discuss measures to mitigate adverse effects.

Physician Accreditation Statement

The Society for Neuro-Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Instructions to Receive Credit, Claim Certificate of Participation 

In order to receive credit or claim your certificate of participation for this activity, the participant must attend the meeting in-person and complete the program evaluation.

A CME/CE evaluation link will be emailed to each participant in the week following the conference conclusion from the Society for Neuro-Oncology with the subject line "Instructions to Claim Credit, or Certificate of Participation for the 2026 SNO/ASCO CNS Metastases Conference."

Physicians should only claim CME credit commensurate with the time they spent in the activity.

For technical assistance with claiming CME credit, please email academy@soc-neuro-onc.org

Deadline to claim CE Credit will be Wednesday October 7, 2026, at 11:59 pm ET.

Refund/Cancellation Policy 

The deadline for cancellations with refund is Monday, July 27, 2026. Cancellations must be received in writing and a $50 cancellation fee will be assessed. Cancellations received after the deadline date cannot be refunded, but the meeting registration can be transferred to another person with written authorization.

Please note that your SNO membership must be current if you have chosen to register as a SNO member. SNO reserves the right to confirm that you have registered in the correct category.

Payment must be received in full before access to the meeting can be granted.

Email all cancellation and transfer requests to Program Registrar Caroline Noor, caroline@soc-neuro-onc.org

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Society for Neuro-Oncology does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

SNO CME Contact Information

For information about the accreditation of this program, please contact the Society for Neuro-Oncology CME Program Manager, MeLesa Buchanan, RN at melesa@soc-neuro-onc.org